AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04654156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Boost post processing technique
Description: Contrast Enhancement Boost is a post-processing technique that uses an iodine density map generated by subtracting a pre- and post-contrast CT acquisition to artificially enhance pulmonary artery enhancement.
Study NCT01866982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
Study NCT01866982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Cord Clamping
Description: Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
Study NCT01037101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Vivo Exposure Therapy
Description: Three hours of exposure therapy in a high place
Study NCT01037101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Three hours of exposure therapy using a virtual reality system
Study NCT01037101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: 50 mg of DCS administered 30 minutes before the session
Study NCT01037101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg of DCS administered 30 minutes before the session
Study NCT01037101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg placebo administered 30 minutes before the session
Study NCT01037101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg placebo administered 30 minutes before the session
Study NCT03826771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power training
Description: high-intensity lower extremity resistance training
Study NCT03826771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: upper and lower body range of motion exercises
Study NCT03783845 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: amoxicillin 500mg and metronidazole 400mg
Description: metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
Study NCT03352817 — intervention group
Intervention type: OTHER
Intervention: Cardiac rehabilitation
Description: A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
Study NCT01987661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP ST
Description: non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
Study NCT01987661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP ST
Description: non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
Study NCT01987661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtrap
Description: Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time.
Study NCT01693276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks.
Study NCT01693276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
Study NCT01693276 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: IMRT Dose escalation: 60 Gy (2 Gy/fraction)
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study NCT03102099 — intervention group
Intervention type: PROCEDURE
Intervention: contrast-enhanced ultrasound group
Description: The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
Study NCT03102099 — intervention group
Intervention type: PROCEDURE
Intervention: conventional ultrasound group
Description: The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
Study NCT03787368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single intravenous infusion of BAY1213790 (Two different doses)
Study NCT03787368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: Single intravenous infusion of Placebo (0.9% sodium chloride solution)
Study NCT04098692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib capsule
Description: 300 mg derazantinib oral administration (3x100 mg capsules)
Study NCT04098692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Derazantinib solution for infusion
Description: 100 μg \[14C\]-derazantinib intravenous administration
Study NCT03519022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study NCT01896700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
Study NCT01896700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating matched dose of placebo
Study NCT03236493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: PF-06700841 will be administered as tablet
Study NCT04098692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Derazantinib capsule
Description: 300 mg \[14C\]-derazantinib oral administration (3x100 mg capsules)
Study NCT03236493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study NCT04647461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 1.5mg
Description: 1 drop 3 times a day for 12 weeks to target eyes
Study NCT04647461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate 1.5mg
Description: 1 drop 3 times a day for 12 weeks to target eyes
Study NCT03222167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/ Grazoprevir 50/100 mg fixed dose combination
Description: Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
Study NCT00065065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4mg orally twice daily for 12 weeks
Study NCT00065065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill that looks identical to rosiglitazone
Study NCT00941252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical imiquimod therapy
Description: therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
Study NCT00941252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical imiquimod therapy
Description: therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
Study NCT04001205 — intervention group
Intervention type: DRUG
Intervention: Anticoagulation Therapy
Description: Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Study NCT01399021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early Drain Removal
Description: Drain will be removed prior to patient's discharge on the day of the surgery
Study NCT01399021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Late Drain Removal
Description: Patient will be seen on the day following the surgery to have the drain removed
Study NCT02264457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: T-flex Aspheric Toric IOL
Study NCT02264457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AT TORBI toric IOL
Study NCT02729493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPCAM-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study NCT01225991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
Study NCT00874900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational game
Description: Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department.
Study NCT00874900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational game + motivational interview
Description: Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
Study NCT00874900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
Study NCT03333681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
Study NCT05683314 — intervention group
Intervention type: PROCEDURE
Intervention: Tranditional open reduction and internal fixation
Description: Under navigation and bone desity projecting method assisted 3D simulation and printing for minimal invasive surgrey
Study NCT03833453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
Study NCT03833453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
Study NCT03833453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT
Description: DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
Study NCT02499185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nephro Check Test
Description: Urine sample
Study NCT02499185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nephro Check Test
Description: Urine sample
Study NCT02499185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum creatinine measurement
Description: Blood sample
Study NCT02499185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum creatinine measurement
Description: Blood sample
Study NCT01269190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Resolution Microendoscopy
Description: Undergo evaluation of oral lesions using a high-resolution microendoscope
Study NCT01269190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multispectral Imaging
Description: Undergo evaluation of oral cavity using a widefield multispectral imaging
Study NCT01269190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: Proflavine) used to stain the mouth tissue after initial imaging.
Study NCT04339543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive dual-task walking
Description: • The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
Study NCT04232085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Preparative regimen
Study NCT04350892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet (VLCD)
Description: Weight loss with calorie restricted liquid diet. Participants will be placed on a 800 kcal/day diet for meal replacement (Optifast) provided by the investigator for 12 weeks. Participants will be monitored weekly by the study dietician and medical staff.
Study NCT02972879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: Orthotic (Group 1)
Description: participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
Study NCT02972879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: LLLT (Group 2)
Description: The LLLT parameters are:~* LASER 904nm~* P: 1.5W/cm²~* 30mV/cm²~* Area 2 cm²~* 1 Joule por ponto ( in the A1 pulley)
Study NCT02972879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic modalities: Paraffin (Group 3)
Description: Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:
Study NCT02972879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (Group 4)
Description: The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
Study NCT05102682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise program using exoskeleton device
Description: Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device
Study NCT03242473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Management
Description: The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
Study NCT03870230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fourier Domain Doppler Optical Coherence Tomography (FDOCT)
Description: Retinal blood flow will be assessed using FDOCT
Study NCT01803672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health talk and adventure-based training
Description: To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
Study NCT01803672 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
Study NCT01051960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan 5mg or 10mg once daily
Study NCT03173118 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ultrasound elastography
Description: Endoscopic ultrasound elastography performed on both groups of patients as per routine
Study NCT01168128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Change Strategy
Description: e.g. Education, decision support tools
Study NCT01545167 — intervention group
Intervention type: GENETIC
Intervention: blood sampling
Description: blood samples obtained to extract biomarkers and dna for analysis, questionnaires
Study NCT03775616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive financial navigation program intervention
Study NCT03775616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03775616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01958437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
Study NCT01958437 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
Study NCT01958437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
Study NCT03146806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: 10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse.